Vimarsana
Biggest News Aggregation in the World

Page 17 - Acceleron Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acceleron Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acceleron Pharma Today - Breaking & Trending Today

Farallon Steps Up Activism at Biotech Company Exelixis. Here's What Could Happen Next - Vimarsana News

Farallon Steps Up Activism at Biotech Company Exelixis. Here's What Could Happen Next

Farallon isn’t an activist investor, but it won’t shy away from a battle if necessary.

Farallon steps up activism at biotech company Exelixis. Here's what could happen next - Vimarsana News

Farallon steps up activism at biotech company Exelixis. Here's what could happen next

Farallon isn’t an activist investor, but it won’t shy away from a battle if necessary.

Source: cnbc.com
Eisenmenger Complex Management Market to reach US$ 12.9 billion in 2033 - Vimarsana News

Eisenmenger Complex Management Market to reach US$ 12.9 billion in 2033

The global Eisenmenger complex management market is expected to surpass an impressive valuation of US$ 7.7 billion in 2023 and is projected to reach US$ 12.9 billion by 2033, growing at a CAGR of 5.3%. Generally, the treatment includes relieving the symptoms and associated co-morbidities. Medications such as calcium...

'Unheard of' PAH Improvement With Novel Drug: STELLAR - Vimarsana News

'Unheard of' PAH Improvement With Novel Drug: STELLAR

Sotatercept, a designer molecule that removes a key driver of pulmonary arterial hypertension, was efficacious and safe in the first of three pivotal trials.

ACC: Sotatercept Boosts Exercise Capacity With Pulmonary Arterial Hypertension - Vimarsana News

ACC: Sotatercept Boosts Exercise Capacity With Pulmonary Arterial Hypertension

FRIDAY, March 10, 2023 (HealthDay News) -- Sotatercept is associated with a greater improvement in exercise capacity than placebo among patients with pulmonary arterial hypertension (PAH) receiving stable background therapy, according to a study published online March 6 in the New England Journal of Medicine to coincide with the annual meeting of the American College